Compare GameStop Corp. (GME) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GameStop Corp. vs Tango Therapeutics Inc. — how do they compare? GameStop Corp. trades at $26.43 (market cap $13.73B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: GameStop Corp. is far larger — about 3.7× Tango Therapeutics Inc.'s market cap, and GameStop Corp. is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GameStop Corp. for 62 Days and Tango Therapeutics Inc. for 0 Days on average.
| GME | TNGX | |
|---|---|---|
Market Cap | $13.73B | $3.75B |
Volume | 12,710,661 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $27.23 | $32.90 |
52-Week Low | $17.87 | $7.50 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $13.01B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GME trades at $27.15, down 0.29% on the day, with a bullish technical signal supported by moving averages. The company reported net income of $131.3M in 2025, a significant turnaround from prior losses, and holds a strong cash position of $4.77B. Recent insider buying by CEO Ryan Cohen has driven positive sentiment, with shares gaining 31% over the past month.
The outlook is mixed; strong cash reserves and insider confidence support upside, but revenue declined to $3.82B in 2025, and analyst consensus remains cautious with only 16.7% buy ratings. Key risks include execution challenges in the retail gaming sector and high valuation multiples relative to historical performance.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
